Regulated information

Sales 3rd quarter 2023: 136M€

The Vetoquinol Group posted sales of €136 million in Q3 2023, up +1.3% on a reported basis and +5.1% at constant exchange rates. Over the same period, Vetoquinol recorded a negative currency impact of -€5 million, linked to the Americas and Asia Pacific/Rest of World territories.

2023 HALF-YEAR RESULTS

Sales: €256m (-5.4% as reported)
Essentials products sales: €151m (59% of Group sales)
Net income - Group share: €32m (12.6% of sales)
EBITDA*: €54m (20.9% of sales)
Cash-flow generation: €31m

Q1 2023 Sales: €145M

Vetoquinol recorded sales of €145 million for the first three months of the 2023 financial year, up 7.7% on a reported basis and 7.2% at constant exchange rates.

Availability of the 2022 universal registration document

On 13 April 2023, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).

2022 ANNUAL RESULTS

Annual sales: €540m (up 3.6% as reported)
Essentials sales: €304m (up 4.5% as reported)
EBIT before depreciation of acquired assets: €99m (18.3% of sales)
Net income - Group share: €48m (8.9% of sales)
EBITDA: €118m (21.9% of sales)
Free cash-flow: €63m

Annual sales 2022

Total group Sales: €540 million (up 3.6% as reported)
Annual Sales of Essential products: €304 million (up 4.5% as reported)

Matthieu Frechin named Managing Director of Vétoquinol

December 14, 2009 (Lure, France) – The Board of Directors of Vétoquinol, at its December 10
meeting, has named Matthieu Frechin Managing Director of the Vétoquinol Group, replacing
Etienne Frechin. He will be seconded by Dominique Henryon, Deputy General Manager.
Etienne Frechin will give up all operating functions but will continue to serve as Chairman of
Vétoquinol’s Board of Directors.

Strong growth in Revenues in the 3rd quarter

Vétoquinol recorded strong growth in the 3rd quarter of 2009, despite an unfavourable exchange rate effect. The strength in sales was due to a combination of the contribution of acquisitions in Italy and India and sustained organic growth.

Vétoquinol posts resilient results in the first half of 2009 and continues to pursue its international growth

The Board of Directors of Vétoquinol, meeting on August 27, reviewed the group’s business and approved the group’s interim 2009 financial statements.

Vétoquinol completes the acquisition of Wockhardt Animal Health in India

August 20, 2009 (Lure, France) – Vétoquinol today announced the completion of its acquisition of the animal health business division of Wockhardt Limited, based in Mumbaï, India. This acquisition was the subject of an agreement signed with the Wockhardt Limited group on June 26.